The first-line treatment for advanced pancreatic cancer

Journal of the Pancreas

Volumn 11, Issue 2, 2010, Pages 148-150

  Merl, Man Yee ^a   Li, Jia ^b   Saif, Muhammad Wasif ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

Erlotinib; Gemcitabine; Pancreatic neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEMCITABINE; IMC A 12; MK 0646; SORAFENIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADVANCED CANCER; ASTHENIA; BLOOD CELL COUNT; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DRUG INFUSION REACTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; LEUKOPENIA; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; UNITED STATES; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CLINICAL TRIALS, PHASE I AS TOPIC; COMBINED MODALITY THERAPY; CONGRESSES AS TOPIC; DISEASE PROGRESSION; GASTROINTESTINAL NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS;

EID: 77749245782     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59:225-49. [PMID 19474385]
2. National Cancer Institute. Pancreatic Cancer Treatment (PDQ® ). Accessed 04 Feb 2010.
3. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13. [PMID 9196156]
4. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010 Jan 26. [PMID 20101258]
5. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6. [PMID 17452677]
6. Javle MM, Varadhachary GR, Bhosale P, Ukegbu L, Overman MJ, Shroff RT, et al. Phase I study of MK-0646, a humanized monoclonal antibody against IGF-1R in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced previously untreated pancreatic cancer. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 131.
7. Philip PA, Goldman BH, Ramanathan RK, Lenz, Lowy AM, Whitehead RP, et al. Phase I trial of combination gemcitabine, erlotinib (NSC-718781), and IMC-A12 (NSC-742460) as first-line treatment in patients with metastatic pancreatic cancer: Southwest Oncology Group study S0727. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 233.
8. Francois E, Bennouna J, Etienne-Grimaldi M, Follana P, Senellart H, Mari V, et al. Phase I clinical trial with gemcitabine (Gem), capecitabine (Cap), and erlotinib (E) combination in advanced pretreated pancreatic carcinoma. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 245.
9. Geissler M, Hofheinz R, Moehler MH, Klöppel G, Bitzer M, Boeck SH, et al. Trastuzumab and capecitabine in patients with HER2-expressing metastatic pancreatic cancer: A multicenter phase II study of the AIO pancreatic cancer group (on behalf of the German AIO group [AIO PK-0204]). 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 200.
10. Backlund DC, Goff LW, Chan E, Shyr Y, Conkright WA, Cornelius LA,et al. A phase II trial of sorafenib (S) and erlotinib (E) in unresectable pancreas cancer: Preliminary results. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 264.